Shots:
- Merck has initiated P-III (KANDLELIT-007) trial of calderasib (MK-1084) + Keytruda Qlex for the 1L treatment of pts with KRAS G12C-mutant, advanced or metastatic nonsquamous NSCLC
- Trial will assess calderasib (PO, QD) + Keytruda Qlex (SC; Q6W) vs Keytruda Qlex + pemetrexed (IV) + CT in ~ 675 newly diagnosed pts with KRAS G12C-mutant nonsq. NSCLC, evaluating PFS as 1EP in pts having PD-L1+ tumors
- Calderasib is in P-III (KANDLELIT-012) trial with cetuximab & mFOLFOX6 in KRAS G12C-mutant colorectal cancer & P-III (KANDLELIT-004) with Keytruda as 1L therapy for KRAS G12C-mutant PD-L1+ NSCLC, alongside P-I (KANDLELIT-001) & P-II (KANDLELIT-014) studies in KRAS G12C-mutant solid tumors
Ref: Merck | Image: Merck | Press Release
Related News: Merck Reports P-III (KEYNOTE-B15) Trial Finding on Keytruda + Padcev to Treat Muscle-Invasive Bladder Cancer (MIBC)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
